Dose-Ranging Study of Sofosbuvir in Combination With Pegylated Interferon and Ribavirin in Treatment Naïve GT 1 HCV Patients
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01054729 |
Recruitment Status
:
Completed
First Posted
: January 22, 2010
Results First Posted
: February 19, 2014
Last Update Posted
: April 17, 2014
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hepatitis C | Drug: Sofosbuvir Drug: Placebo Drug: PEG Drug: RBV | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 64 participants |
Allocation: | Randomized |
Intervention Model: | Single Group Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | A Multi-center, Double-Blind, Parallel Group, Randomized, Placebo-Controlled, Dose Ranging Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Oral Administration of PSI-7977 in Combination With Standard of Care (Pegylated Interferon and Ribavirin) in Treatment-Naïve Patients With Chronic HCV Infection Genotype 1 |
Study Start Date : | January 2010 |
Actual Primary Completion Date : | April 2010 |
Actual Study Completion Date : | August 2011 |
Arm | Intervention/treatment |
---|---|
Experimental: Sofosbuvir 100 mg+PEG+RBV
Participants received sofosbuvir 100 mg (1 x 100 mg tablet) and placebo to match sofosbuvir (3 tablets) for 28 days (baseline to Day 28), plus PEG+RBV (baseline to Week 48)
|
Drug: Sofosbuvir
Sofosbuvir tablet(s) administered orally once daily
Other Names:
Drug: PEG
Pegylated interferon alfa-2a (PEG) 180 μg was administered once weekly by subcutaneous injection.
Other Name: Pegasys®
Drug: RBV
Ribavirin (RBV) tablets were administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).
Other Name: Copegus®
|
Experimental: Sofosbuvir 200 mg+PEG+RBV
Participants received sofosbuvir 200 mg (2 x 100 mg tablets) and placebo to match sofosbuvir (2 tablets) for 28 days (baseline to Day 28), plus PEG+RBV (baseline to Week 48)
|
Drug: Sofosbuvir
Sofosbuvir tablet(s) administered orally once daily
Other Names:
Drug: PEG
Pegylated interferon alfa-2a (PEG) 180 μg was administered once weekly by subcutaneous injection.
Other Name: Pegasys®
Drug: RBV
Ribavirin (RBV) tablets were administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).
Other Name: Copegus®
|
Experimental: Sofosbuvir 400 mg+PEG+RBV
Participants received sofosbuvir 400 mg (4 x 100 mg tablets) for 28 days (baseline to Day 28), plus PEG+RBV (baseline to Week 48)
|
Drug: Sofosbuvir
Sofosbuvir tablet(s) administered orally once daily
Other Names:
Drug: PEG
Pegylated interferon alfa-2a (PEG) 180 μg was administered once weekly by subcutaneous injection.
Other Name: Pegasys®
Drug: RBV
Ribavirin (RBV) tablets were administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).
Other Name: Copegus®
|
Active Comparator: Placebo+PEG+RBV
Participants received placebo to match sofosbuvir (4 tablets) for 28 days (baseline to Day 28), plus PEG+RBV (baseline to Week 48)
|
Drug: Placebo
Placebo to match sofosbuvir administered orally once daily
Drug: PEG
Pegylated interferon alfa-2a (PEG) 180 μg was administered once weekly by subcutaneous injection.
Other Name: Pegasys®
Drug: RBV
Ribavirin (RBV) tablets were administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).
Other Name: Copegus®
|
- Percentage of Participants Who Experienced Adverse Events During the Sofosbuvir Treatment Period [ Time Frame: Baseline to Week 4 ]Adverse events (AEs) occurring during the sofosbuvir treatment period were summarized across the participant population. A participant was counted once if they had a qualifying event.
- Change in Circulating HCV RNA at Week 4 [ Time Frame: Baseline to Week 4 ]
- Percentage of Participants With Rapid Virologic Response at Week 4 [ Time Frame: Week 4 ]Rapid virologic response (RVR) was defined as HCV RNA below the limit of detection (LOD [15 IU/mL]) at Week 4.
- Percentage of Participants With Sustained Virologic Response (SVR) at 12 and 24 Weeks After Last Dose of PEG+RBV Following Completion of 48 Weeks of Treatment [ Time Frame: Post-treatment Weeks 12 and 24 ]SVR at 12 weeks (SVR12) and 24 weeks (SVR24) was defined as HCV RNA < LOD 12 and 24 weeks after last dose of PEG+RBV, respectively, following completion of 48 weeks of treatment (4 weeks of sofosbuvir or matching placebo and PEG+RBV, followed by an additional 44 weeks of PEG+RBV).
- Plasma Pharmacokinetics of Sofosbuvir: Cmax at Day 0 [ Time Frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 12 hours postdose ]
The Cmax of sofosbuvir was measured at Day 0 following a single dose of sofosbuvir.
Cmax is defined as the maximum concentration of drug.
- Plasma Pharmacokinetics of Sofosbuvir: Cmax at Day 27 [ Time Frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours postdose) ]The Cmax of sofosbuvir was measured at Day 27 following continuous dosing of sofosbuvir.
- Plasma Pharmacokinetics of Sofosbuvir: AUCinf at Day 0 [ Time Frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 12 hours postdose ]
The AUCinf of sofosbuvir was analyzed at Day 0 (following a single dose of sofosbuvir).
AUCinf is defined as the concentration of drug (area under the plasma concentration versus time curve) extrapolated to infinite time.
- Plasma Pharmacokinetics of Sofosbuvir: AUCtau at Day 27 [ Time Frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours postdose) ]
The AUCtau of sofosbuvir was analyzed at Day 27 (following continuous dosing of sofosbuvir).
AUCtau is defined as the concentration of drug (area under the plasma concentration versus time curve) over the dosing interval.
- Plasma Pharmacokinetics of GS-331007: Cmax at Day 0 [ Time Frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 12 hours postdose ]The Cmax of GS-331007 was measured at Day 0 following a single dose of sofosbuvir. GS-331007 is the predominant circulating metabolite of sofosbuvir.
- Plasma Pharmacokinetics of GS-331007: Cmax at Day 27 [ Time Frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours postdose) ]The Cmax of GS-331007 was measured at Day 27 following continuous dosing of sofosbuvir.
- Plasma Pharmacokinetics of GS-331007: AUCinf at Day 0 [ Time Frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 12 hours postdose ]The AUCinf of GS-331007 was analyzed at Day 0 (following a single dose of sofosbuvir).
- Plasma Pharmacokinetics of GS-331007: AUCtau at Day 27 [ Time Frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours postdose) ]The AUCtau of GS-331007 was analyzed at Day 27 (following continuous dosing of sofosbuvir).
- Plasma Pharmacokinetics of GS-566500: Cmax at Day 0 [ Time Frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 12 hours postdose ]The Cmax of GS-566500 was measured at Day 0 following a single dose of sofosbuvir. GS-566500 is one of the major metabolites of sofosbuvir.
- Plasma Pharmacokinetics of GS-566500: Cmax at Day 27 [ Time Frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours postdose) ]The Cmax of GS-566500 was measured at Day 27 following continuous dosing of sofosbuvir.
- Plasma Pharmacokinetics of GS-566500: AUCinf at Day 0 [ Time Frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 12 hours postdose ]The AUCinf of GS-566500 was analyzed at Day 0 (following a single dose of sofosbuvir).
- Plasma Pharmacokinetics of GS-566500: AUCtau at Day 27 [ Time Frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours postdose) ]The AUCtau of GS-566500 was analyzed at Day 27 (following continuous dosing of sofosbuvir).
- Percentage of Participants Who Developed Resistance to Sofosbuvir [ Time Frame: Baseline to Week 4 ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Treatment-naive males and females, 18-65 years of age
- Genotype 1 HCV infection
- Negative pregnancy test for females of childbearing age
- Females of childbearing age and males with female partners of childbearing age must use two forms of contraception during treatment and following the last dose of ribavirin in accordance with locally approved label for ribavirin
Exclusion Criteria:
- Hepatitis B or HIV infection
- Pregnant or breast feeding females or male partners of pregnant females
- Previous interferon or ribavirin-based therapy or investigational anti-HCV agent
- History or evidence of medical condition associated with chronic liver disease other than HCV

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01054729
United States, California | |
Quest Clinical Research | |
San Francisco, California, United States, 94115 | |
United States, Florida | |
University of Florida | |
Gainesville, Florida, United States, 32610 | |
Orlando Immunology Center | |
Orlando, Florida, United States, 32803 | |
United States, North Carolina | |
Duke University | |
Durham, North Carolina, United States, 27710 | |
United States, Texas | |
Alamo Medical Research Center | |
San Antonio, Texas, United States, 78215 | |
United States, Washington | |
Virginia Mason Medical Center | |
Seattle, Washington, United States, 98101 | |
Puerto Rico | |
Fundacion de Investigacion de Diego | |
Santurce, Puerto Rico, 00909 |
Study Director: | Robert H. Hyland, DPhil | Gilead Sciences |
Responsible Party: | Gilead Sciences |
ClinicalTrials.gov Identifier: | NCT01054729 History of Changes |
Other Study ID Numbers: |
P7977-0221 |
First Posted: | January 22, 2010 Key Record Dates |
Results First Posted: | February 19, 2014 |
Last Update Posted: | April 17, 2014 |
Last Verified: | March 2014 |
Keywords provided by Gilead Sciences:
Chronic Hepatitis C infection Genotype 1 HCV GT1 GT 1 |
Additional relevant MeSH terms:
Hepatitis Hepatitis C Liver Diseases Digestive System Diseases Hepatitis, Viral, Human Virus Diseases Flaviviridae Infections RNA Virus Infections |
Interferons Ribavirin Sofosbuvir Antineoplastic Agents Antiviral Agents Anti-Infective Agents Antimetabolites Molecular Mechanisms of Pharmacological Action |